47.47
price down icon0.88%   -0.42
pre-market  プレマーケット:  46.86   -0.61   -1.29%
loading
前日終値:
$47.89
開ける:
$47.58
24時間の取引高:
2.47M
Relative Volume:
0.95
時価総額:
$115.01B
収益:
$43.23B
当期純損益:
$6.79B
株価収益率:
11.85
EPS:
4.0051
ネットキャッシュフロー:
$9.17B
1週間 パフォーマンス:
-1.37%
1か月 パフォーマンス:
-0.73%
6か月 パフォーマンス:
-1.35%
1年 パフォーマンス:
-3.85%
1日の値動き範囲:
Value
$47.10
$47.63
1週間の範囲:
Value
$46.67
$49.34
52週間の値動き範囲:
Value
$44.62
$60.12

Sanofi Adr Stock (SNY) Company Profile

Name
名前
Sanofi Adr
Name
セクター
Healthcare (1114)
Name
電話
-
Name
住所
-
Name
職員
82,878
Name
Twitter
@sanofi
Name
次回の収益日
2025-10-24
Name
最新のSEC提出書
Name
SNY's Discussions on Twitter

SNY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
SNY
Sanofi Adr
47.47 116.03B 43.23B 6.79B 9.17B 4.0051
Drug Manufacturers - General icon
LLY
Lilly Eli Co
1,032.97 960.61B 59.42B 18.41B 6.44B 20.22
Drug Manufacturers - General icon
JNJ
Johnson Johnson
219.57 526.55B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
216.75 392.16B 59.64B 2.36B 19.68B 1.3253
Drug Manufacturers - General icon
MRK
Merck Co Inc
110.97 275.53B 63.90B 19.05B 13.05B 7.5596
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
143.15 280.45B 54.45B 14.42B 17.15B 7.333

Sanofi Adr Stock (SNY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-06 ダウングレード Barclays Overweight → Equal Weight
2025-12-09 ダウングレード Guggenheim Buy → Neutral
2025-12-08 ダウングレード JP Morgan Overweight → Neutral
2025-09-08 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-09-02 アップグレード Deutsche Bank Hold → Buy
2025-08-08 アップグレード JP Morgan Neutral → Overweight
2025-04-15 開始されました Exane BNP Paribas Outperform
2025-03-21 開始されました Goldman Neutral
2025-01-30 アップグレード Deutsche Bank Sell → Hold
2024-07-26 繰り返されました Argus Buy
2024-01-23 開始されました Morgan Stanley Equal-Weight
2024-01-16 再開されました UBS Buy
2023-12-05 ダウングレード JP Morgan Overweight → Neutral
2023-10-30 ダウングレード Stifel Buy → Hold
2023-09-06 アップグレード Berenberg Hold → Buy
2023-07-14 開始されました HSBC Securities Buy
2023-04-28 ダウングレード Deutsche Bank Hold → Sell
2023-03-27 アップグレード Barclays Equal Weight → Overweight
2022-12-13 再開されました Morgan Stanley Overweight
2022-08-12 アップグレード Deutsche Bank Sell → Hold
2022-08-09 ダウングレード UBS Buy → Neutral
2022-05-23 開始されました SVB Leerink Outperform
2021-09-27 アップグレード SVB Leerink Mkt Perform → Outperform
2021-01-15 開始されました Deutsche Bank Sell
2020-09-29 開始されました Berenberg Hold
2020-03-17 アップグレード Barclays Underweight → Equal Weight
2020-03-11 アップグレード Goldman Neutral → Buy
2020-02-11 開始されました SVB Leerink Mkt Perform
2020-01-06 アップグレード JP Morgan Neutral → Overweight
2019-09-23 アップグレード Guggenheim Neutral → Buy
2019-09-20 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-09-03 開始されました Bernstein Outperform
2019-08-14 アップグレード UBS Neutral → Buy
2018-12-11 アップグレード Jefferies Hold → Buy
2018-11-01 アップグレード Barclays Underweight → Equal Weight
2018-10-09 開始されました Guggenheim Neutral
2018-09-10 アップグレード BofA/Merrill Neutral → Buy
2018-08-10 アップグレード Citigroup Neutral → Buy
2018-03-23 アップグレード Liberum Hold → Buy
2018-01-23 ダウングレード Barclays Equal Weight → Underweight
2017-12-06 ダウングレード BofA/Merrill Buy → Neutral
2017-12-01 ダウングレード Morgan Stanley Overweight → Underweight
2017-11-15 アップグレード Barclays Underweight → Equal Weight
2017-08-30 アップグレード HSBC Securities Reduce → Hold
すべてを表示

Sanofi Adr (SNY) 最新ニュース

pulisher
Jan 15, 2026

Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz

Jan 15, 2026
pulisher
Jan 15, 2026

FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks - Benzinga

Jan 15, 2026
pulisher
Jan 13, 2026

Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz

Jan 13, 2026
pulisher
Jan 12, 2026

Sanofi (SNY) Reports Regulatory Win, Barclays Downgrades to 'Equal Weight' with EUR 85 PT - Finviz

Jan 12, 2026
pulisher
Jan 09, 2026

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail

Jan 09, 2026
pulisher
Jan 07, 2026

Regeneron Just Moved From Underperform To Buy - Benzinga

Jan 07, 2026
pulisher
Jan 05, 2026

KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz

Jan 05, 2026
pulisher
Jan 05, 2026

Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz

Jan 05, 2026
pulisher
Jan 05, 2026

FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children - Finviz

Jan 05, 2026
pulisher
Jan 02, 2026

REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz

Jan 02, 2026
pulisher
Dec 31, 2025

Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm

Dec 31, 2025
pulisher
Dec 30, 2025

Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Finviz

Dec 30, 2025
pulisher
Dec 30, 2025

Where is Sanofi (SNY) Headed According to Wall Street? - Finviz

Dec 30, 2025
pulisher
Dec 29, 2025

Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges - Finviz

Dec 29, 2025
pulisher
Dec 28, 2025

Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Finviz

Dec 28, 2025
pulisher
Dec 25, 2025

Total debt per share of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView — Track All Markets

Dec 25, 2025
pulisher
Dec 24, 2025

Why Dynavax Stock Soared Today - Finviz

Dec 24, 2025
pulisher
Dec 24, 2025

Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz

Dec 24, 2025
pulisher
Dec 24, 2025

Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy - Sahm

Dec 24, 2025
pulisher
Dec 24, 2025

Our Environmental Impact - Sanofi

Dec 24, 2025
pulisher
Dec 21, 2025

Bloom Energy Aktie: KI-Boom trifft auf Energiekrise! - Finanztrends

Dec 21, 2025
pulisher
Dec 17, 2025

Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades - Finviz

Dec 17, 2025
pulisher
Dec 16, 2025

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Dec 16, 2025
pulisher
Dec 15, 2025

Sanofi (SNY) sees slight pessimism from analysts - MSN

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi: Today's Tolebrutinib Setback Shouldn't Worry ShareholdersThis Is Why (SNY) - Seeking Alpha

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration - Sahm

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks - Sahm

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025) - ts2.tech

Dec 15, 2025
pulisher
Dec 14, 2025

SNY Stock Price and Chart — NASDAQ:SNY - TradingView — Track All Markets

Dec 14, 2025
pulisher
Dec 12, 2025

Sanofi (SNY) Sees Slight Pessimism From Analysts - Finviz

Dec 12, 2025
pulisher
Dec 10, 2025

JPMorgan Downgrades Sanofi (SNY) to EUR 95 from EUR 105 - Finviz

Dec 10, 2025
pulisher
Dec 10, 2025

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz

Dec 10, 2025
pulisher
Dec 10, 2025

Why Wall Street Analysts Are Closely Watching Sanofi (SNY) - Finviz

Dec 10, 2025
pulisher
Dec 09, 2025

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz

Dec 09, 2025
pulisher
Dec 09, 2025

KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz

Dec 09, 2025
pulisher
Dec 09, 2025

Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Sahm

Dec 09, 2025
pulisher
Dec 01, 2025

REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Finviz

Dec 01, 2025

Sanofi Adr (SNY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general BMY
$56.62
price down icon 0.70%
drug_manufacturers_general PFE
$25.89
price up icon 1.21%
$121.26
price down icon 2.26%
$330.03
price up icon 0.32%
drug_manufacturers_general NVO
$57.12
price down icon 3.04%
drug_manufacturers_general NVS
$143.15
price down icon 2.06%
大文字化:     |  ボリューム (24 時間):